Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

474
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
474
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

673
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
673
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

428
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
428
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

551
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
551
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

574
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
574

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypertrophic Cardiomyopathy and Sudden Cardiac Death: All in the Family?

JACC. Clinical electrophysiology·2026
Same author

Notch1 deletion reduces arrhythmogenic remodeling after myocardial infarction.

Heart rhythm·2026
Same author

A custom analysis of R-R interval properties reveals alterations in the brain-heart axis in experimental animals with metabolic syndrome.

Heart rhythm O2·2026
Same author

Risk factors and outcomes associated with failed implantable cardioverter-defibrillator shocks.

Heart rhythm·2025
Same author

Varied Successful Ablation Sites of Nodoventricular/Nodofascicular Pathway-Mediated Tachycardias.

JACC. Clinical electrophysiology·2025
Same author

Risk of recurrent ventricular tachyarrhythmia following the occurrence of a first ventricular arrhythmic event in patients with a primary prevention implantable cardioverter-defibrillator.

Heart rhythm·2024

Related Experiment Video

Updated: Feb 28, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Cardiac Resynchronization Therapy for Heart Failure.

Amole Ojo1, Sohaib Tariq1, Prakash Harikrishnan1

  • 1Division of Cardiology, Westchester Medical Center, New York Medical College, 100 Woods Road, Valhalla, NY 10595, USA.

Interventional Cardiology Clinics
|June 11, 2017
PubMed
Summary
This summary is machine-generated.

Cardiac resynchronization therapy (CRT) improves heart failure outcomes by optimizing left ventricular function and reducing mitral regurgitation in patients with left bundle branch block. It offers significant benefits, but patient selection is key for optimal response.

Keywords:
Biventricular pacingCardiac resynchronization therapyDyssynchronyHeart failure with reduced ejection fraction

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.0K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.3K

Related Experiment Videos

Last Updated: Feb 28, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.0K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.3K

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Management

Background:

  • Heart failure with reduced ejection fraction (HFrEF) and ventricular dyssynchrony, often due to left bundle branch block (LBBB), are significant clinical challenges.
  • Cardiac resynchronization therapy (CRT) is a nonpharmacologic treatment option for selected HFrEF patients.

Purpose of the Study:

  • To review the rationale, effects, and indications for CRT in heart failure patients.
  • To discuss patient characteristics predicting CRT response and strategies for nonresponders.

Main Methods:

  • Review of existing literature on CRT mechanisms, efficacy, and patient selection.
  • Analysis of studies investigating echocardiographic and clinical predictors of CRT response.

Main Results:

  • CRT can lead to reverse remodeling, increased ejection fraction (EF), and decreased mitral regurgitation severity.
  • Specific patient characteristics, such as LBBB morphology and QRS duration, predict CRT response.

Conclusions:

  • CRT is a valuable therapy for appropriately selected heart failure patients with LBBB.
  • Understanding response predictors is crucial for optimizing CRT outcomes and managing nonresponders.